ALX Oncology Holdings Inc income statement

In fiscal 2022, ALX Oncology Holdings Inc reported revenue of $0 and net income of −$123m, or −$3.03 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

ALX Oncology Holdings Inc: income statement, annual
Fiscal year	2018Dec 2018	2019Dec 2019	2020Dec 2020	2021Dec 2021	2022Dec 2022
Revenue	2	5	1	0	0
Research and development	11	16	29	60	98
General and administrative	3	3	15	23	29
Operating income	−14	−19	−44	−84	−127
Interest expense	—	—	—	0	0
Income before tax	−14	−19	−45	−83	−123
Income tax	0	0	0	−0	0
Net income	−14	−19	−46	−83	−123
Diluted EPS	−$6.33	−$7.56	−$2.76	−$2.07	−$3.03
Diluted shares (average)	3m	3m	18m	40m	41m
EBITDA	−13	−19	−43	−84	−127

US$ millions unless shown otherwise. Fiscal quarters.

ALX Oncology Holdings Inc: income statement, quarterly
Quarter	2019 Q2Jun 2019	2019 Q3Sept 2019	2019 Q4Dec 2019	2020 Q1Mar 2020	2020 Q2Jun 2020	2020 Q3Sept 2020	2020 Q4Dec 2020
Revenue	1	1	1	1	1	0	0
Research and development	4	2	7	4	8	5	12
General and administrative	1	1	1	1	3	4	6
Operating income	−4	−3	−8	−5	−11	−10	−18
Interest expense	—	—	—	—	0	0	—
Income before tax	−4	−3	−8	−5	−11	−10	−19
Income tax	0	0	0	0	0	0	0
Net income	−4	−3	−9	−5	−11	−10	−19
Diluted EPS	−$1.68	−$1.33	−$2.84	−$2.37	−$4.41	−$0.36	−$0.09
EBITDA	−4	−3	−8	−5	−11	−10	−18

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from ALX Oncology Holdings Inc's SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to ALX Oncology Holdings Inc.